Treatment-refractory cutaneous Rosai–Dorfman disease responsive to oral methotrexate and topical trametinib

• Christopher J. Fay, BA,
• Dorsa Moslehi, BA,
• Christopher Iriarte, MD,
• Timothy M. Dang, MD,
• Cesar A. Virgen, MD, PhD,
• Eleanor Russell-Goldman, MD, PhD,
• Nicole R. LeBoeuf, MD, MPH

Affiliations

Christopher J. Fay, BA

Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts; Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts

Dorsa Moslehi, BA

Harvard Medical School, Boston, Massachusetts

Christopher Iriarte, MD

Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts; Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts

Timothy M. Dang, MD

Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts; Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts

Cesar A. Virgen, MD, PhD

Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts; Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts

Eleanor Russell-Goldman, MD, PhD

Harvard Medical School, Boston, Massachusetts; Department of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts

Nicole R. LeBoeuf, MD, MPH

Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts; Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts; Correspondence to: Nicole R. LeBoeuf, MD, MPH, Center for Cutaneous Oncology, Dana-Farber/Brigham Cancer Center, 450 Brookline Ave, Boston, MA 02115.